Healthcare & Pharmaceuticals

Published by
The New York Times
|
By |
A Congressional investigation of the money that drug companies give as supposed educational grants has found that the payments are growing rapidly and are sometimes steered by marketing executives to doctors and groups who push unapproved uses of drugs. Read More
Published by
The New York Times
|
By |
The Food and Drug Administration yesterday released a warning letter it sent to the Guidant Corporation, restricting the ability of the company to win approval for some new medical products. In the letter, sent a week ago, the agency said Guidant, the heart device maker, had not fully responded to its concerns about manufacturing procedures at the company's biggest plant. Read More
Published by
The New York Times
|
By |
LOS ANGELES, Aug. 25 - The attorney general of California sued 39 drug companies on Thursday, accusing them of bilking the state of hundreds of millions of dollars by overcharging for medicines. Read More
Published by
New York Times
|
By |
The Supreme Court ruled, in one of its most closely watched property rights cases in years, that fostering economic development is an appropriate use of the government's power of eminent domain. Read More
Published by
Boston Globe
|
By |
David Franklin, the drug company whistle-blower who has sparked federal and state investigations into the marketing of the top-selling drug Neurontin, said yesterday that he and his former colleagues engaged in a series of inappropriate tactics, including misleading doctors to persuade them to prescribe the drug for unapproved uses. Read More
Published by
Los Angeles Times
|
By |
Few industries campaigned harder than pharmaceutical manufacturers to elect Republicans to the new Congress, and few industries are better positioned to reap the rewards of the election returns, analysts said Thursday. Read More
* indicates required